DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Military Burn
  4. Research Highlights/News
  5. 2022 Military Burn Research Program

Military Burn

NEWS RELEASE

Released: March 18, 2022

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Military Burn Research Program
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)

The FY22 Defense Appropriation provides funding for the MBRP to support advanced technology development to improve burn care outcomes. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The MBRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY22 MBRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY22 MBRP must address one or more of the following Focus Areas:

  • Atypical Burns: Development and/or validation of methods to prevent, triage, and/or treat burns resulting from exposure to cold, radiation, directed energy weapons, or high-voltage/combat-related electrical injuries. Novel interventions that move beyond topical agents or dressings are of particular interest.
  • Burn Injury During Mass Casualty: Solutions to improve the triage, delivery, or capacity of care after burn mass casualty events
  • Burn injury related complications: Development and/or validation of methods to prevent, assess, and/or treat burn injury-related complications, including:
    • Over/under fluid resuscitation to include limited or low volume resuscitation
    • Acute respiratory distress syndrome (ARDS)
    • Sepsis
    • Inhalation injuries


Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Translational Research Award (CTRA) Investigators at all academic levels (or equivalent)
  • Intended to support human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point-of-injury, or during the acute phase of injury.
  • Impact is a key component of this award mechanism and should be clearly described.
  • The proposed study must include clinical research, and may include initial proof-of-concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
  • Large randomized clinical trials are discouraged.
  • Preliminary data is required.
  • Animal research is not allowed.
  • Pre-application submission is required; application submission is by invitation only.
  • Maximum funding of $2.21M for total costs (direct costs plus indirect costs).
  • Maximum period of performance is 4 years.
Technology/Therapeutic Development Award(TTDA) Investigators at all academic levels (or equivalent)
  • Intended to support the translation of promising preclinical findings into products for clinical applications.
  • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
  • Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established.
  • Preliminary data is required.
  • Clinical trials are not allowed.
  • Pre-application submission is required; application submission is by invitation only.
  • Maximum funding of $2.21M for total costs (direct costs plus indirect costs).
  • Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil